Amylin Pharmaceuticals Inc. on Tuesday said it has accelerateddevelopment of its amylin hormone analog, and plans to file aninvestigational new drug application by the end of the third quarter.The trial had been targeted for the end of the year.
The San Diego company (NASDAQ:AMLN) said it will test thecompound, AC137, as a treatment for emergency low blood suger indiabetics who take too much insulin. AC137 mimics the naturalhormone amylin, which regulates the body's handling of glucose.
AC137, which will be the company's first product, eventually will betested as an adjunct to insulin in treating type I diabetes.Amylin shares closed Tuesday at $15.13, down $2.13. -- RF
(c) 1997 American Health Consultants. All rights reserved.